Table 1.
Overview of FDA approved ADCs.
mAb | Drug | Drugs/Ab (average) | Chemistry | Reducable | Trigger | Status (US) | Ref |
---|---|---|---|---|---|---|---|
Gemtuzumab ozogamicin | Calicheamicin | 4-6 (5*) | Lysine | yes | pH | approved (2000) & withdrawn (2010) | [148] |
Brentuximab vedotin | Monomethyl auristatin E (MMAE) | 3-5 (4) | Cysteine | no | protease | approved (2011) | [143] |
Trastuzumab emtansine | Mertansine (DM1) | 0-8 (3.5) | Lysine | no | none | approved (2013) | [140] |
For only 50% of the antibodies